Rimonabant

• UNSPSC Description:

  Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

• Target Antigen:

  Bacterial; Cannabinoid Receptor

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;GPCR/G Protein;Neuronal Signaling

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Infection; Metabolic Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Rimonabant.html

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC=C(C=C1)C2=C(C(C(NN3CCCCC3)=O)=NN2C4=CC=C(C=C4Cl)Cl)C

• Molecular Weight:

  463.79

• References & Citations:

  [1]Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct;63(5):905-15.|[2]Zhang B, et al. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. Cell. 2019 Jan 24;176(3):636-648.e13.|[3]Erdozain, A. M. et al. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain Biochemical Pharmacology (2012), 83(2), 260-268.|[4]Leite, C.E., et al. Rimonabant: An antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 61 217-224 (2009).Autophagy. 2021 Nov;17(11):3592-3606.|Cell. 2019 Jan 24;176(3):636-648.e13. |Int J Mol Sci. 2024 May 3;25(9):5012.|Structure. 2022 Aug 7;S0969-2126(22)00278-7.|Cancers (Basel). 2021 Jan 18;13(2):330.|Neuroscience. 2019 Feb 19. pii: S0306-4522(19)30117-4.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  168273-06-1